A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Inclusion Criteria: 1. Fully understand the study and voluntarily sign the informed consent form; 2. Age between 18 and 75 years; 3. Histologically confirmed resectable or potentially resectable locally advanced gastric/gastroesophageal junction adenocarcinoma; 4. Tumor Regression Grade (TRG) 2 or 3 after preoperative adjuvant therapy; 5. R0 resection after neoadjuvant chemotherapy; 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 7. Life expectancy of at least 2 years; 8. No prior anti-cancer treatment received; 9. Good compliance and cooperation with follow-up. Exclusion Criteria: 1. Inability to comply with the study protocol or procedures; 2. History of prior gastric cancer surgery; 3. Contraindications to surgical treatment and chemotherapy or physical condition and organ function that do not allow for major abdominal surgery; 4. Distant metastasis to organs other than the liver, such as lung, brain, and bone; 5. Known HER2-positive patients; 6. Uncontrolled hypertension despite medication prior to enrollment; 7. Poorly controlled diabetes despite medication prior to enrollment; 8. Urine routine indicating proteinuria ≥2+, and a 24-hour urine protein quantification \>1.0g; 9. Presence of conditions requiring intervention such as bleeding, perforation, or obstruction prior to enrollment; 10. Patients deemed ineligible for this study by the investigator.